Regulation of A1 by OX40 Contributes to CD8+ T Cell Survival and Anti-Tumor Activity

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lei, Fengyang ^a   Song, Jianyong ^b   Haque, Rizwanul ^a   Haque, Mohammad ^a   Xiong, Xiaofang ^a   Fang, Deyu ^c   Croft, Michael ^d   Song, Jianxun ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; CD134 ANTIGEN; GAMMA INTERFERON; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; ENZYME REGULATION; GENE INACTIVATION; GENETIC TRANSDUCTION; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR IMMUNITY; TUMOR VOLUME; UPREGULATION; WILD TYPE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; GENE KNOCKOUT TECHNIQUES; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, OX40; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84880979723     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070635     Document Type: Article

References (41)

1. Croft M, (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: 57-78.
2. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M, (2004) Costimulation of CD8 T cell responses by OX40. J Immunol 172: 4821-4825.
3. Song A, Tang X, Harms KM, Croft M, (2005) OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol 175: 3534-3541.
4. Lee SW, Park Y, Song A, Cheroutre H, Kwon BS, et al. (2006) Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol 177: 4464-4472.
5. Mousavi SF, Soroosh P, Takahashi T, Yoshikai Y, Shen H, et al. (2008) OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. J Immunol 181: 5990-6001.
6. Bekiaris V, Gaspal F, Kim MY, Withers DR, Sweet C, et al. (2009) Synergistic OX40 and CD30 signals sustain CD8+ T cells during antigenic challenge. Eur J Immunol 39: 2120-2125.
7. Hendriks J, Xiao Y, Rossen JW, van der Sluijs KF, Sugamura K, et al. (2005) During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol 175: 1665-1676.
8. Humphreys IR, Loewendorf A, de Trez C, Schneider K, Benedict CA, et al. (2007) OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T Cells: A CD4-dependent mechanism. J Immunol 179: 2195-2202.
9. Salek-Ardakani S, Moutaftsi M, Crotty S, Sette A, Croft M, (2008) OX40 drives protective vaccinia virus-specific CD8 T cells. J Immunol 181: 7969-7976.
10. Sanchez PJ, Kedl RM, (2012) An alternative signal 3: CD8(+) T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling. Vaccine 30: 1154-1161.
11. Boettler T, Moeckel F, Cheng Y, Heeg M, Salek-Ardakani S, et al. (2012) OX40 facilitates control of a persistent virus infection. PLoS Pathog 8: e1002913.
12. Ruby CE, Redmond WL, Haley D, Weinberg AD, (2007) Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. Eur J Immunol 37: 157-166.
13. Salek-Ardakani S, Moutaftsi M, Sette A, Croft M, (2011) Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection. J Virol 85: 9051-9059.
14. Salek-Ardakani S, Flynn R, Arens R, Yagita H, Smith GL, et al. (2011) The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J Clin Invest 121: 296-307.
15. Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, et al. (2006) OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 176: 974-983.
16. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD, (2007) Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 179: 7244-7253.
17. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, et al. (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68: 5206-5215.
18. Redmond WL, Gough MJ, Weinberg AD, (2009) Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol 39: 2184-2194.
19. Yang Y, Liu C, Peng W, Lizee G, Overwijk WW, et al. (2012) Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120: 4533-4543.
20. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, et al. (2004) The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol 5: 150-158.
21. Song J, So T, Croft M, (2008) Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 180: 7240-7248.
22. Ottina E, Grespi F, Tischner D, Soratroi C, Geley S, et al. (2012) Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 119: 6032-6042.
23. Fan G, Simmons MJ, Ge S, Dutta-Simmons J, Kucharczak J, et al. (2010) Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood 115: 3559-3569.
24. Kucharczak JF, Simmons MJ, Duckett CS, Gelinas C, (2005) Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. Cell Death Differ 12: 1225-1239.
25. Herold MJ, Zeitz J, Pelzer C, Kraus C, Peters A, et al. (2006) The stability and anti-apoptotic function of A1 are controlled by its C terminus. J Biol Chem 281: 13663-13671.
26. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N, (2007) Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 26: 5828-5832.
27. Gonzalez J, Orlofsky A, Prystowsky MB, (2003) A1 is a growth-permissive antiapoptotic factor mediating postactivation survival in T cells. Blood 101: 2679-2685.
28. Chuang PI, Morefield S, Liu CY, Chen S, Harlan JM, et al. (2002) Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1. Blood 99: 3350-3359.
29. Zhao B, Song A, Haque R, Lei F, Weiler L, et al. (2009) Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression. J Immunol 182: 6744-6752.
30. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, et al. (2009) Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113: 1982-1991.
31. Song J, So T, Cheng M, Tang X, Croft M, (2005) Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22: 621-631.
32. Ottina E, Tischner D, Herold MJ, Villunger A, (2012) A1/Bfl-1 in leukocyte development and cell death. Exp Cell Res 318: 1291-1303.
33. Mandal M, Borowski C, Palomero T, Ferrando AA, Oberdoerffer P, et al. (2005) The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J Exp Med 201: 603-614.
34. Xiang Z, Ahmed AA, Moller C, Nakayama K, Hatakeyama S, et al. (2001) Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation. J Exp Med 194: 1561-1569.
35. Orlofsky A, Weiss LM, Kawachi N, Prystowsky MB, (2002) Deficiency in the anti-apoptotic protein A1-a results in a diminished acute inflammatory response. J Immunol 168: 1840-1846.
36. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, et al. (2009) Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113: 4403-4413.
37. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M, (2001) OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15: 445-455.
38. So T, Soroosh P, Eun SY, Altman A, Croft M, (2011) Antigen-independent signalosome of CARMA1, PKCtheta, and TNF receptor-associated factor 2 (TRAF2) determines NF-kappaB signaling in T cells. Proc Natl Acad Sci U S A 108: 2903-2908.
39. So T, Choi H, Croft M, (2011) OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling. J Immunol 186: 3547-3555.
40. Song J, Salek-Ardakani S, So T, Croft M, (2007) The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol 8: 64-73.
41. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, et al. (2002) 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 169: 4882-4888.